Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)
|ClinicalTrials.gov Identifier: NCT00251576|
Recruitment Status : Completed
First Posted : November 10, 2005
Last Update Posted : April 10, 2017
A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner.
Z-Phase: To evaluate early treatment of patients with long term chest pain (using an approved drug for 30 days, followed by an increased dose of the drug) as compared to patients (treated with diet and 4 months placebo followed by diet and approved drug) in patients who have experienced acute chest pain or heart attack.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome||Drug: A-Phase: tirofiban; Z-Phase simvastatin Drug: Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years Drug: Comparator: A-Phase: low molecular weight heparin, unfractionated heparin Drug: Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours Drug: Duration of Treatment: Z-Phase, 2 years.||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4497 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction With Aspirin|
|Actual Study Start Date :||November 1, 1999|
|Primary Completion Date :||March 23, 2004|
|Study Completion Date :||March 23, 2004|
- Z-Phase: combined frequency of the following clinical endpoint events: cardiovascular death, MI, readmission for ACS.
- Z-Phase: the incidence of the following endpoints, evaluated individually and as a composite: cardiovascular death, MI, readmission for ACS, coronary revascularization due to documented ischemia and non-hemorrhagic stroke.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00251576
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|